Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers

Thumbnail Image
Download
Name

c4sc02130d.pdf

Size

770.38 KB

Format

Adobe PDF

Checksum (MD5)

0d0b1db8791d82c9e31c4067f743e60b

Download all files submitted through automated deposit
sword-2017-12-11.original.zip (590.7 KB)
Author(s)
Wagner, F. F.
•
Zhang, Y.-L.
•
Fass, D. M.
•
Gale, J. P.
•
Weïwer, M.
•
McCarren, P.
•
Fisher, S. L.
•
Kaya, T.
•
Zhao, W.-N.
•
Reis, S. A.
more
Date Issued
October 2014
Journal
Chemical Science
Publisher
Royal Society of Chemistry (RSC)
Citation
Wagner, F. F., et al. “Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.” Chemical Science, vol. 6, no. 1, 2015, pp. 804–15. © The Royal Society of Chemistry
Version
Final published version
Abstract
Aiming towards the development of novel nootropic therapeutics to address the cognitive impairment common to a range of brain disorders, we set out to develop highly selective small molecule inhibitors of HDAC2, a chromatin modifying histone deacetylase implicated in memory formation and synaptic plasticity. Novel ortho-aminoanilide inhibitors were designed and evaluated for their ability to selectively inhibit HDAC2 versus the other Class I HDACs. Kinetic and thermodynamic binding properties were essential elements of our design strategy and two novel classes of ortho-aminoanilides, that exhibit kinetic selectivity (biased residence time) for HDAC2 versus the highly homologous isoform HDAC1, were identified. These kinetically selective HDAC2 inhibitors (BRD6688 and BRD4884) increased H4K12 and H3K9 histone acetylation in primary mouse neuronal cell culture assays, in the hippocampus of CKp25 mice, a model of neurodegenerative disease, and rescued the associated memory deficits of these mice in a cognition behavioural model. These studies demonstrate for the first time that selective pharmacological inhibition of HDAC2 is feasible and that inhibition of the catalytic activity of this enzyme may serve as a therapeutic approach towards enhancing the learning and memory processes that are affected in many neurological and psychiatric disorders.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-NonCommercial 3.0 Unported
https://creativecommons.org/licenses/by-nc/3.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/112747
DOI of Published Version
https://doi.org/10.1039/C4SC02130D
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.